DexCom posted another quarter of robust top-line growth that leaves the firm on track to meet our full-year expectations, and we’re standing behind our $315 fair value estimate. Importantly, DexCom’s ...

What’s the next CGM step change, and how is Dexcom going to deliver it? That’s one of the fundamental questions Jake Leach has been asked since stepping into the role of CEO at Dexcom. “I want to make ...

BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, there is no expected impact to the timing of 15-day FDA ...

Dexcom today unveiled its next-generation continuous glucose monitor (CGM), the G8 system, at its Investor Day event.

DexCom (NASDAQ:DXCM) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...

Diabetes is a disease in which there is too much sugar in a person's blood. Type 2 diabetes is most common and is caused by factors such as obesity or lack of exercise. Rising obesity rates are a big ...